Your browser doesn't support javascript.
loading
Evaluation of bioequivalence and safety analysis of capecitabine tablets and Xeloda® under postprandial dosing conditions in Chinese patients with solid tumor.
Li, Hongtao; Shan, Rongfang; Ding, Jiaxiang; Zhang, Jialin; Liu, Bingyan; Ge, Qin; Cheng, Dongmei; Li, Lufeng; Zhang, Chaoyang; Su, He; Li, Xiaoyue; Li, Huiru; Ye, Jingjing; Li, Hui; Li, Fengxian; Zhou, Huan; Huo, Qiang; Su, Yue.
Afiliación
  • Li H; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Shan R; Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Ding J; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Zhang J; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China.
  • Liu B; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Ge Q; School of Public Basic, Bengbu Medical College, Bengbu, Anhui, China.
  • Cheng D; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Li L; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Zhang C; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Su H; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Li X; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Li H; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Ye J; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Li H; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Li F; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Zhou H; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Huo Q; Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Su Y; Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Expert Opin Drug Metab Toxicol ; 19(12): 1015-1021, 2023 Dec.
Article en En | MEDLINE | ID: mdl-38059472
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Expert Opin Drug Metab Toxicol Asunto de la revista: METABOLISMO / TOXICOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Expert Opin Drug Metab Toxicol Asunto de la revista: METABOLISMO / TOXICOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido